Moleculin Biotech (NASDAQ:MBRX) Now Covered by StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of Moleculin Biotech (NASDAQ:MBRX) in a note issued to investors on Sunday. The brokerage set a “sell” rating on the stock.

A number of other research firms have also recently commented on MBRX. Roth Mkm restated a “buy” rating and issued a $40.00 price target on shares of Moleculin Biotech in a report on Friday, April 12th. Maxim Group reduced their price target on shares of Moleculin Biotech from $45.00 to $20.00 and set a “buy” rating for the company in a report on Tuesday, March 26th.

Moleculin Biotech Stock Performance

NASDAQ:MBRX opened at $3.66 on Friday. The firm has a fifty day simple moving average of $4.51 and a two-hundred day simple moving average of $6.86. Moleculin Biotech has a 12 month low of $3.35 and a 12 month high of $15.75.

Moleculin Biotech (NASDAQ:MBRX) last posted its quarterly earnings results on Friday, May 10th. The company reported ($2.02) EPS for the quarter, topping analysts’ consensus estimates of ($3.59) by $1.57. Equities research analysts anticipate that Moleculin Biotech will post -8.79 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Moleculin Biotech stock. Atticus Wealth Management LLC acquired a new stake in shares of Moleculin Biotech, Inc. (NASDAQ:MBRX) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 50,001 shares of the company’s stock, valued at approximately $43,000. Atticus Wealth Management LLC owned about 0.17% of Moleculin Biotech at the end of the most recent reporting period. 15.52% of the stock is currently owned by institutional investors and hedge funds.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.